By Carlo Martuscelli

GlaxoSmithKline PLC (GSK.LN) said Friday that it was pleased to note that the U.K.'s fraud watchdog closed its investigation into the company without requiring any further action.

The Serious Fraud Office's case dates back to May 2014, when it began to investigate the FTSE 100-listed drugmaker over bribery charges in China. A court in the Asian country found one of Glaxo's local subsidiaries guilty of bribery, and fined the company $491.5 million in September 2014.

Earlier in the month Glaxo had said that the SFO had requested more information on its use of third-party advisers.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

February 22, 2019 06:52 ET (11:52 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Gsk.